Investigation of the cellular and soluble markers of inflammation for the assessment of cardiovascular risk in patients with acute coronary syndrome in Bangladesh

Aim To study the efficacy and safety of alirocumab in patients with high and very high cardiovascular risk in the Republic of Karelia and to evaluate their compliance with the alirocumab therapy.Materials and methods Study design: observational, noncomparative. The observation group consisted of 9 patients receiving alirocumab (Praluent®) (mean age, 48.6±4.7 years; 7 men). 7 patients had familial hypercholesterolemia of the type diagnosed by DLCN criteria; five patients had MI. Lipid profile, concentrations of transaminases, creatinine, glucose, and lipoprotein a (LP(a)) were measured at 3, 6, 12, and 18 months. Electrocardiography was performed, and the clinical picture (development of acute coronary syndrome, acute cerebrovascular disease, transient ischemic attacks, myocardial revascularization, and cardiovascular death) was evaluated. Efficacy criteria included the absence of these clinical conditions, the proportion of patients who achieved the LDL CS goal, and the decrease in LP(a). Safety was evaluated by clinical and laboratory data, such as levels of transaminases, total bilirubin, creatinine, and blood glucose. The observation lasted for 6 months to 1.5 years.Results LDL CS goals were achieved in 7 (77.8%) patients receiving alirocumab. The mean level of LP(a) decreased from 0.39 to 0.28 g/l; the degree of decrease ranged from 20 to 33 %. No cases of IHD instability (acute coronary syndrome) or new cases of acute cerebrovascular disease and transient ischemic attacks were observed. None of the patients had to stop the alirocumab treatment; adverse effects, including local ones, were not observed.Conclusion LDL CS goals were achieved in 7 (77.8%) patients. The level of LP(a) decreased by 20-33% in patients receiving the PCSK9 inhibitor. In real-life clinical practice, the alirocumab treatment was characterized with high compliance and good tolerability without side effects, including local ones.

Download Full-text

Corrected QT Interval Prolongation: A New Predictor of Cardiovascular Risk in Patients With Non-ST-Elevation Acute Coronary Syndrome

Revista Española de Cardiología (English Edition) ◽

10.1016/s1885-5857(08)60180-2 ◽

2008 ◽

Vol 61 (6) ◽

pp. 572-578 ◽

Cited By ~ 1

Author(s):

Francisco L. Gadaleta ◽

Susana C. Llois ◽

Víctor A. Sinisi ◽

Juan Quiles ◽

Pablo Avanzas ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Cardiovascular Risk ◽

Qt Interval ◽

Interval Prolongation ◽

Corrected Qt Interval ◽

Coronary Syndrome ◽

Qt Interval Prolongation ◽

St Elevation ◽

Elevation Acute Coronary Syndrome

Download Full-text

Prior Use of Medication for Primary Prevention in Patients with Coronary Syndrome

Journal of Primary Care & Community Health ◽

10.1177/2150132720946949 ◽

2020 ◽

Vol 11 ◽

pp. 215013272094694

Author(s):

Andrés Gaviria-Mendoza ◽

Julián Andrés Zapata-Carmona ◽

Andrés Alirio Restrepo-Bastidas ◽

Carmen Luisa Betancur-Pulgarín ◽

Jorge Enrique Machado-Alba

Keyword(s):

Acute Coronary Syndrome ◽

Cardiovascular Risk ◽

Primary Prevention ◽

Risk Score ◽

High Intensity ◽

Real Life ◽

Risk Scores ◽

Coronary Syndrome ◽

Cardiovascular Risk Score ◽

Clinical Records

Background: Cardiovascular disease, especially coronary disease, represents one of the main causes of morbidity and mortality. Objective: To determine the drug prescription profile for primary cardiovascular prevention prior to a first acute coronary syndrome event. Methods: Cross-sectional study. We included adult patients of any sex affiliated with one healthcare insurer of the Colombian Health System, with a diagnosis of a first episode of acute coronary syndrome that occurred during the period of 2015 to 2016. Sociodemographic, clinical and pharmacological variables were evaluated from clinical records. The cardiovascular risk score prior to the event was calculated, and the need for the use of statins and aspirin in primary prevention was defined according to the recommendations of clinical practice guidelines. Results: Clinical records of 322 patients were reviewed with mean age of 61.9 ± 10.8 years, and 77.3% were men. The most frequent comorbidities were dyslipidemia (64.3%), arterial hypertension (62.7%) and diabetes mellitus (30.1%); 22% of the patients were obese, and 33.5% were smokers. The cardiovascular risk score was calculated in 211 patients (65.5%) who had the necessary variables complete. The median 10-year risk according to Framingham risk score was 21.4%, and it was 16.3% according to the American Heart Association. From the 211 patients with risk scores, there were 179 (84.8%) who needed statins (175 of high intensity, 97.8%), and 88 (27.3%) required aspirin as a primary prevention; however, 56 of these patients (31.3%) did not receive any statins, 127 (72.6%) did not receive the high intensity statin they needed, and 38 (43.2% of those with indication) lacked aspirin. Conclusion: Real-life data show that among a group of patients with high cardiovascular risk, a substantial proportion were not receiving medications for primary prevention necessary to reduce their risk and finally suffered an acute coronary event.

Download Full-text